| Description |
Acute myeloid leukemia (AML) is a malignant hematological cancer with the worst prognosis of all leukemia categories. Here, we reported a comprehensive proteogenomic analysis of 101 Chinese AML patients, including proteomic, phosphoproteomic analysis and an ex vivo drug sensitivity analysis in addition to Whole exome and transcriptome sequencing. We explored the impact of genomic alterations on proteomic and phosphoproteomic characterizations, and also uncovered the protein and phosphosite panel as prognostic indicators. Proteome-based unsupervised clustering revealed three subtypes with different molecular characterizations and clinical outcomes. Further integrative analysis of drug sensitivity combined with proteomic data showed the novel therapeutic potential of cytarabine-disulfiram combo and PI3Ki-PDKi combo. Our data provided valuable resources for understanding the molecular alterations in AML pathogenesis and clinical therapeutic strategies. |